Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Cell Therapy News
Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
CRISPR-Cas Therapies Targeting Bacteria
[Nature Reviews Bioengineering] Investigators explore how the CRISPR–Cas toolbox can be engineered to kill or modify specific bacteria.
Layered-Responsive Multivalent Tetrahedral DNA Framework-Decorated CRISPR-Cas12a Nanocapsule Enables Precise and Enhanced Tumor Chemotherapy
[ACS Nano] Scientists developed a self-controlled DNA nanostructure-CRISPR-12a system, a triple-locked cascade tumor therapy nanocapsule, for efficient and targeted tumor treatment.
Programmable Gene Insertion in Human Cells with a Laboratory-Evolved CRISPR-Associated Transposase
[Science] Scientists established CRISPR-associated transposase as a powerful platform technology for efficient, RNA-guided gene integration in human cells.
An AAV Variant Selected through NHP Screens Robustly Transduces the Brain and Drives Secreted Protein Expression in NHPs and Mice
[Science Translational Medicine] Investigators performed in vivo screens of millions of peptide-modified capsid variants of AAV1, AAV2, and AAV9 parental serotypes in adult nonhuman primates to identify capsids with potent transduction of key brain tissues, including ependyma, after intracerebroventricular injection.
IL-21 Loading CaMnCO3 Vitality Backpacks Boost CAR-T Cell Synergistic Immunotherapy
[Small] Acid-sensitive responsive CaMnCO3 nanoparticles were developed that simultaneously mitigate tumor microenvironment acidosis and hypoxia.
Immunotherapy-Related Cognitive Impairment after CAR T Cell Therapy in Mice
[Cell] Investigators demonstrated in mouse models that CAR T cell therapy for both central nervous system and non-CNS cancers impaire cognitive function and induced a persistent CNS immune response characterized by white matter microglial reactivity, microglial chemokine expression, and elevated cerebrospinal fluid cytokines and chemokines.
SOLVE FSHD Announces $3 Million Investment in Armatus Bio to Advance Gene Therapy Program for FSHD
[SOLVE FSHD] SOLVE FSHD announced a $3 million investment in Armatus Bio. The investment will support ARM-201, Armatus Bio’s AAV-delivered microRNA therapy designed to silence the expression of DUX4, the toxic protein responsible for muscle degeneration in individuals with facioscapulohumeral muscular dystrophy (FSHD).
New Awards Aim to Make Minnesota a Leader in Regenerative Medicine
[Mayo Clinic ] Regenerative Medicine Minnesota has awarded funding to three projects aimed at strengthening Minnesota's capabilities for developing and delivering therapies that replace, restore, rejuvenate or regenerate damaged cells, tissues or organs.
ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy
[Bio-Techne Corporation] ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, announced that March Biosciences has been awarded a $200,000 G-Rex® Grant.
CAR Binders Affect CAR T Cell Tonic Signaling, Durability, and Sensitivity to Target
[Cancer Immunology Research] Investigators screened a yeast display library to identify an array of fully human CD19 single-chain variable fragment binders and performed a series of studies to select the most promising fully human CAR.
Engineering TME-Gated Inducible CAR-T Cell Therapy for Solid Tumors
[Molecular Therapy] Investigators presented a novel strategy using a genetic “AND" gate that integrates chemically-induced proximity and tumor-activated prodrug approaches to generate TME-iCAR-T cell that are capable of sensing multiple tumor-specific characteristics to precisely execute therapeutic functions within the TME.
HPV16-Expressing Tumors Release Multiple IL-1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine
[Cancer Discovery] Researchers showed that human papillomavirus type 16 (HPV16)–driven squamous cell tumors in the cervix and skin release into the circulatory system four immunoregulatory ligands, IL-1α, IL-1β, IL-33, and IL-36β, that bias the bone marrow toward granulocytic myelopoiesis.
Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.
